Arcus Biosciences (NYSE:RCUS) Trading Down 5% – Should You Sell?

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) traded down 5% on Monday . The stock traded as low as $14.90 and last traded at $14.92. 247,348 shares were traded during mid-day trading, a decline of 66% from the average session volume of 733,496 shares. The stock had previously closed at $15.70.

Analyst Upgrades and Downgrades

RCUS has been the topic of several recent analyst reports. Evercore ISI raised Arcus Biosciences to a “strong-buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “neutral” rating and set a $20.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Finally, Barclays lifted their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Arcus Biosciences currently has an average rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Stock Performance

The firm has a fifty day moving average of $16.62 and a 200-day moving average of $16.10. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.32 billion, a P/E ratio of -4.88 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.06. The company had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.94) EPS. Research analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current fiscal year.

Institutional Trading of Arcus Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in RCUS. Vanguard Group Inc. grew its stake in shares of Arcus Biosciences by 2.4% during the first quarter. Vanguard Group Inc. now owns 4,791,244 shares of the company’s stock worth $90,459,000 after purchasing an additional 110,528 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Arcus Biosciences by 8.7% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 744,298 shares of the company’s stock worth $11,336,000 after purchasing an additional 59,273 shares in the last quarter. SG Americas Securities LLC lifted its stake in Arcus Biosciences by 1,396.1% in the second quarter. SG Americas Securities LLC now owns 129,292 shares of the company’s stock valued at $1,969,000 after buying an additional 120,650 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Arcus Biosciences by 17.8% during the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock worth $2,866,000 after acquiring an additional 28,307 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Arcus Biosciences in the 2nd quarter valued at $1,286,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.